United Kingdom & GT Biopharma

United Kingdom: The United Kingdom participated in the PAES study, contributing to the data that supports the efficacy and safety of Imlifidase.

GT Biopharma: GT Biopharma announced positive topline results from its European Post Authorization Efficacy Study for Imlifidase, fulfilling a key requirement for full marketing authorization and boosting its product's market potential.

United Kingdom: The United Kingdom>>> is one of the regions where SERB Pharmaceuticals>>> will acquire rights to Imlifidase>>>.

GT Biopharma: GT Biopharma>>> divested the European and MENA rights to Imlifidase for 115 million euros, allowing it to focus on other markets and receive significant payments.

United Kingdom: United Kingdom is one of the international markets where CannEpil has been authorized for importation and prescription through the Named Patient Request framework.

GT Biopharma: GT Biopharma licensed its CannEpil therapeutic to Splash Beverage Group globally. GT Biopharma will receive a 15% royalty on net revenue from worldwide sales of CannEpil and had approximately $5 million of its indebtedness forgiven by Mercer Street Global Opportunity Fund.

United Kingdom: The UK is one of the markets where Idefirix is conditionally approved, part of the product's European footprint.

GT Biopharma: GT Biopharma achieved a commercial milestone with the first commercial use of Idefirix in Australia, supporting its growth strategy. The company continues to advance regulatory processes, including the FDA BLA review.

GT Biopharma: GT Biopharma announced that results from its US Phase 3 ConfIdeS trial in kidney transplantation have been accepted for an oral presentation at the American Transplant Congress, which is a positive development for the company's imlifidase product.